title: Immunotherapy with IL-10- and IFN-γ-producing CD4 effector cells modulate "Natural" and "Inducible" CD4 TReg cell subpopulation levels: observations in four cases of patients with ovarian cancer.
abstract: Adoptive T cell therapy for cancer patients optimally requires participation of CD4 T cells. In this phase I/II study, we assessed the therapeutic effects of adoptively transferred IL-10- and IFN-γ-producing CD4 effector cells in patients with recurrent ovarian cancer. Using MUC1 peptide and IL-2 for ex vivo CD4 effector cell generation, we show that three monthly treatment cycles of autologous T cell restimulation and local intraperitoneal re-infusion-modulated T cell-mediated immune responses that were associated with enhanced patient survival. One patient remains disease-free, another patient experienced prolonged survival for nearly 16 months with recurrent disease, and two patients expired within 3-5 months following final infusion. Prolonged survivors showed elevated levels of systemic CD3(+)CD4(+)CD25(+) and CD3(+)CD4(+)CD25(-) T cells when compared to that of pre-treatment levels and similarly treated short-term survivors. Such cell populations among these patients contained variable levels of "Inducible" Tr1 (CD4(+)CD25(-)FoxP3(-)IL-10(+)) and "Natural" (CD4(+)CD25(+)CD45RO(+)FoxP3(+)) TReg cell numbers and ratios that were associated with prolonged and/or disease-free survival. Moreover, peptide-restimulated T cells from these patients showed an elevation in both IFN-γ production, memory cell phenotype, and select TNF family ligands associated with enhanced T cell survival and apoptosis-inducing activities. This suggests that intraperitoneally administered Th1-like cells, producing elevated levels of IL-10, may require and/or induce differential levels of distinct systemic TReg subpopulations that influence, in part, long-term tumor immunity and enhanced memory/effector CD4-mediated therapeutic potentials. Furthermore, treatment efficacy and enhanced memory cell phenotype did not appear to be dependent on TReg cell numbers but upon ratios of "Inducible" and "Natural" TReg subpopulations.
authors.affiliation: Department of Internal Medicine, Texas Tech University School of Medicine, Amarillo, TX 79106, USA. mark.dobrzanski@ttuhsc.edu
authors.forename: Mark J
authors.initials: MJ
authors.lastname: Dobrzanski
authors.forename: Kathleen A
authors.initials: KA
authors.lastname: Rewers-Felkins
authors.forename: Khaliquzzaman A
authors.initials: KA
authors.lastname: Samad
authors.forename: Imelda S
authors.initials: IS
authors.lastname: Quinlin
authors.forename: Catherine A
authors.initials: CA
authors.lastname: Phillips
authors.forename: William
authors.initials: W
authors.lastname: Robinson
authors.forename: David J
authors.initials: DJ
authors.lastname: Dobrzanski
authors.forename: Stephen E
authors.initials: SE
authors.lastname: Wright
mesh_terms: D000368:Aged; D005260:Female; D006801:Humans; D007167:Immunotherapy; D007371:Interferon-gamma / Q000096:biosynthesis / Q000276:immunology*; D016753:Interleukin-10 / Q000276:immunology*; D008875:Middle Aged; D018396:Mucin-1 / Q000276:immunology; D010051:Ovarian Neoplasms / Q000235:genetics / Q000276:immunology* / Q000628:therapy*; D010641:Phenotype; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*
chemical_list: D018396:Mucin-1; D016753:Interleukin-10; D007371:Interferon-gamma
references.citation: Immunol Cell Biol. 2011 Mar;89(3):346-51
references.pmid: 21301480
references.citation: Cancer Res. 2005 May 15;65(10):3998-4004
references.pmid: 15899788
references.citation: Clin Cancer Res. 2005 Dec 1;11(23):8326-31
references.pmid: 16322292
references.citation: Curr Opin Immunol. 2009 Apr;21(2):224-32
references.pmid: 19304470
references.citation: Cancer Res. 1998 Nov 15;58(22):5066-70
references.pmid: 9823312
references.citation: Cancer Res. 2009 Nov 15;69(22):8700-9
references.pmid: 19843867
references.citation: J Immunol. 2000 Sep 1;165(5):2783-9
references.pmid: 10946310
references.citation: J Immunol. 2008 Sep 15;181(6):4363-70
references.pmid: 18768895
references.citation: J Immunol. 1996 Jul 1;157(1):231-8
references.pmid: 8683120
references.citation: Nat Rev Immunol. 2010 Mar;10(3):170-81
references.pmid: 20154735
references.citation: J Leukoc Biol. 2005 Nov;78(5):1043-51
references.pmid: 16204623
references.citation: Clin Immunol. 2009 Dec;133(3):333-52
references.pmid: 19762283
references.citation: Nat Rev Cancer. 2009 Mar;9(3):167-81
references.pmid: 19238149
references.citation: J Clin Oncol. 2009 Jan 10;27(2):186-92
references.pmid: 19064967
references.citation: Nat Rev Immunol. 2009 Apr;9(4):271-85
references.pmid: 19319144
references.citation: J Immunol. 2006 Jul 15;177(2):896-904
references.pmid: 16818744
references.citation: J Clin Oncol. 2009 Apr 10;27(11):1746-52
references.pmid: 19255331
references.citation: J Exp Med. 2009 May 11;206(5):1009-17
references.pmid: 19414553
references.citation: J Immunol. 2001 Sep 1;167(5):2479-86
references.pmid: 11509586
references.citation: Eur J Immunol. 2003 Nov;33(11):3213-9
references.pmid: 14579290
references.citation: CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
references.pmid: 19474385
references.citation: J Immunol. 2010 May 15;184(10):5654-62
references.pmid: 20400704
references.citation: Immunol Invest. 2008;37(4):315-38
references.pmid: 18569073
references.citation: Immunity. 2009 May;30(5):656-65
references.pmid: 19464988
references.citation: J Exp Med. 2004 Jun 7;199(11):1595-605
references.pmid: 15184507
references.citation: Int J Mol Med. 2002 Apr;9(4):401-4
references.pmid: 11891536
references.citation: Blood. 2007 Jun 15;109(12):5346-54
references.pmid: 17327412
references.citation: Cancer Res. 2001 Jun 15;61(12):4766-72
references.pmid: 11406550
references.citation: Immunol Rev. 2008 Apr;222:101-16
references.pmid: 18363996
references.citation: Nat Rev Immunol. 2006 Nov;6(11):836-48
references.pmid: 17063185
references.citation: J Immunol. 1991 Jul 15;147(2):528-34
references.pmid: 1906502
references.citation: Nat Rev Immunol. 2010 Jul;10(7):490-500
references.pmid: 20559327
references.citation: Proc Natl Acad Sci U S A. 2009 Feb 10;106(6):1903-8
references.pmid: 19174509
references.citation: Immunol Rev. 2008 Jun;223:114-31
references.pmid: 18613832
references.citation: J Immunol. 2005 Oct 1;175(7):4433-40
references.pmid: 16177085
references.citation: Cell. 2008 May 30;133(5):775-87
references.pmid: 18510923
references.citation: J Exp Med. 1996 Aug 1;184(2):579-84
references.pmid: 8760811
references.citation: Cancer Invest. 2005;23(5):399-403
references.pmid: 16193639
references.citation: Clin Cancer Res. 2003 Feb;9(2):606-12
references.pmid: 12576425
references.citation: Gut. 2002 Feb;50(2):191-5
references.pmid: 11788558
references.citation: J Immunol. 2005 May 1;174(9):5382-9
references.pmid: 15843536
references.citation: Nat Med. 2004 Sep;10(9):942-9
references.pmid: 15322536
references.citation: Clin Dev Immunol. 2010;2010:139304
references.pmid: 21076522
references.citation: J Immunol. 2006 Jun 15;176(12):7726-35
references.pmid: 16751420
references.citation: J Exp Med. 2003 Nov 3;198(9):1369-80
references.pmid: 14581610
references.citation: Nature. 1997 Oct 16;389(6652):737-42
references.pmid: 9338786
references.citation: Immunity. 2009 May;30(5):636-45
references.pmid: 19464986
references.citation: Cancer Immunol Immunother. 2007 Jan;56(1):70-80
references.pmid: 16555057
references.citation: Cancer Res. 2011 Feb 15;71(4):1263-71
references.pmid: 21303976
references.citation: J Immunol. 2006 Dec 1;177(11):8191-201
references.pmid: 17114496
references.citation: Nat Rev Immunol. 2010 Dec;10(12):849-59
references.pmid: 21107346
references.citation: Int J Cancer. 2010 Aug 15;127(4):748-58
references.pmid: 20473951
references.citation: Nat Rev Immunol. 2007 Jun;7(6):425-8
references.pmid: 17525751
references.citation: J Exp Med. 2007 Feb 19;204(2):239-43
references.pmid: 17296790
references.citation: Int J Cancer. 2010 Aug 15;127(4):759-67
references.pmid: 20518016
references.citation: Immunol Rev. 2008 Apr;222:129-44
references.pmid: 18363998
references.citation: Scand J Immunol. 2008 Jan;67(1):24-9
references.pmid: 18021186
references.citation: Nat Rev Immunol. 2006 Apr;6(4):295-307
references.pmid: 16557261
references.citation: J Clin Oncol. 2008 Nov 10;26(32):5233-9
references.pmid: 18809613
references.citation: J Immunol. 2006 Aug 15;177(4):2565-74
references.pmid: 16888018
references.citation: Curr Opin Immunol. 2009 Apr;21(2):200-8
references.pmid: 19285848
references.citation: Nat Immunol. 2009 Nov;10(11):1178-84
references.pmid: 19783988
references.citation: J Clin Invest. 2006 Sep;116(9):2434-41
references.pmid: 16906223
references.citation: J Exp Med. 2008 Apr 14;205(4):825-39
references.pmid: 18362171
references.citation: J Immunol. 2010 Sep 15;185(6):3583-92
references.pmid: 20713884
references.citation: Blood. 2001 Oct 1;98(7):2143-51
references.pmid: 11568001
references.citation: J Immunol. 1998 Apr 1;160(7):3188-93
references.pmid: 9531274
references.citation: Cell. 2010 Mar 19;140(6):883-99
references.pmid: 20303878
references.citation: Immunol Cell Biol. 2010 Nov-Dec;88(8):769-70
references.pmid: 20714338
references.citation: J Transl Med. 2006 Dec 13;4:52
references.pmid: 17166272
references.citation: Blood. 2005 Apr 1;105(7):2845-51
references.pmid: 15591118
references.citation: Nat Immunol. 2000 Nov;1(5):433-40
references.pmid: 11062504
references.citation: Blood. 2005 Nov 1;106(9):2995-3003
references.pmid: 16030195
references.citation: Clin Immunol. 1999 Sep;92(3):224-34
references.pmid: 10479527
references.citation: J Clin Invest. 2004 Nov;114(10):1372-8
references.pmid: 15545984
references.citation: J Clin Invest. 2006 Sep;116(9):2423-33
references.pmid: 16955142
references.citation: Mucosal Immunol. 2010 May;3(3):239-46
references.pmid: 20200511
references.citation: N Engl J Med. 2008 Jun 19;358(25):2698-703
references.pmid: 18565862
references.citation: Immunol Rev. 2006 Aug;212:28-50
references.pmid: 16903904